Pelvic inflammatory disease medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 24: Line 24:
===Antibiotic therapy===
===Antibiotic therapy===
====Parenteral treatment====
====Parenteral treatment====
Parenteral therapy has more benefit than oral/intramuscular therapy
*Parenteral therapy has more benefit than oral/intramuscular therapy
*Clinical experience should guide decisions regarding transition to oral therapy, which usually can be initiated within 24–48 hours of clinical improvement.
 
 


{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center

Revision as of 16:18, 21 October 2016


Pelvic inflammatory disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Pelvic Inflammatory Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pelvic inflammatory disease medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pelvic inflammatory disease medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pelvic inflammatory disease medical therapy

CDC on Pelvic inflammatory disease medical therapy

Pelvic inflammatory disease medical therapy in the news

Blogs on Pelvic inflammatory disease medical therapy

to Hospitals Treating Pelvic inflammatory disease

Risk calculators and risk factors for Pelvic inflammatory disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: :Abdurahman Khalil, M.D. [2]

Overview

Empiric antimicrobial therapy must be administered to all patients with a confirmed diagnosis of pelvic inflammatory disease. Hospitalization may be necessary for patients who are pregnant, immunodeficient, and those with severe disease. Combination (rather than monotherapy) is recommended to increase coverage, including gram-negative anaerobes. Antimicrobial therapies generally include doxycycline and a β-lactam. Metronidazole may be added to cover anaerobic bacteria.

Medical Therapy

  • Treatment should be initiated as soon as the presumptive diagnosis has been made to decrease the risk of complications.
  • The long term prognosis is highly dependent on immediate appropriate antibiotic therapy.
  • Combination (rather than monotherapy) is recommended to increase coverage, including gram-negative anaerobes.
  • Patients are usually treated as outpatients.

Indications for hospital admission:

  • Surgical emergencies (e.g., appendicitis) cannot be excluded
  • Tubo-ovarian abscess
  • Pregnancy
  • Severe illness, nausea and vomiting, or high fever
  • Unable to follow or tolerate an outpatient oral regimen
  • No clinical response to oral antimicrobial therapy.


Antibiotic therapy

Parenteral treatment

  • Parenteral therapy has more benefit than oral/intramuscular therapy
  • Clinical experience should guide decisions regarding transition to oral therapy, which usually can be initiated within 24–48 hours of clinical improvement.


Rout of administration Regimen
Parenteral

Preferred:

Cefotetan 2 g IV every 12 hours
PLUS
Doxycycline 100 mg orally or IV every 12 hours

Cefoxitin 2 g IV every 6 hours
PLUS
Doxycycline 100 mg orally or IV every 12 hours

Clindamycin 900 mg IV every 8 hours
PLUS
Gentamicin loading dose IV or IM (2 mg/kg),
followed by a maintenance dose (1.5 mg/kg) every 8 hours.
Single daily dosing (3–5 mg/kg) can be substituted

Alternative:

Ampicillin/Sulbactam 3 g IV every 6 hours
PLUS
Doxycycline 100 mg orally or IV every 12 hours
  • Intramuscular/oral therapy can be considered for women with mild-to-moderately severe acute PID, because the clinical outcomes among women treated with these regimens are similar to those treated with intravenous therapy.
  • Women who do not respond to IM/oral therapy within 72 hours should be reevaluated to confirm the diagnosis and should be administered intravenous therapy.[1]








  • Empiric therapy
  • 1. Parenteral Treatment [2]
  • Preferred regimen (1): (Cefotetan 2 g IV q12h for 14 days OR Cefoxitin 2 g IV q6h) for 14 days AND Doxycycline 100 mg PO or IV q12h starting on day 2-3 until day 14
  • Preferred regimen (2): Clindamycin 900 mg IV q8h for 14 days AND Gentamicin loading dose IV or IM (2 mg/kg of body weight) followed by a maintenance dose (1.5 mg/kg) q8h for 14 days. Single daily dosing (3-5 mg/kg) can be substituted.
  • Alternative regimen (1): Ampicillin/Sulbactam 3 g IV q6h for 14 days AND Doxycycline 100 mg PO or IV q12h for 14 days
  • Alternative regimen (2): Azithromycin 500 mg IV q24 for 1-2 doses followed by 250 mg PO for 5-6 days
  • Alternative regimen (3): Azithromycin 500 mg IV q24 for 1-2 doses followed by 250 mg PO for 5-6 days AND Metronidazole 500 mg PO bid for 12 days
  • Note: Oral doxycycline is preferred since IV doxycycline may cause pain. The bioavailabilities of both oral and IV doxycycline are similar.
  • 2. IM / Oral Treatment
  • Specific considerations
  • Tubo-ovarian abscess

Follow-up

  • Patients should return for re-evaluation at the third day of antimicrobial therapy to evaluate for the success vs. failure of therapy.
  • Patients who do not improve within 3 days of therapy may require hospitalization, additional diagnostic tests, and surgical intervention.
  • Women with documented chlamydial or gonococcal infections have a high rate of reinfection within 6 months of treatment.
  • Repeat testing of all women who have been diagnosed with chlamydia or gonorrhea is recommended 3–6 months after treatment, regardless of whether their sex partners were treated. All women diagnosed with acute PID should be offered HIV testing.

Treatment of Sexual Partners

  • Male partners of women who have PID are often asymptomatic.
  • Both symptomatic and asymptomatic sexual partners of patients with pelvic inflammatory disease should be also be evaluated and treated.

References

  1. Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, Sondheimer SJ, Hendrix SL, Amortegui A, Trucco G, Songer T, Lave JR, Hillier SL, Bass DC, Kelsey SF (2002). "Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial". Am. J. Obstet. Gynecol. 186 (5): 929–37. PMID 12015517.
  2. Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC) (2010). "Sexually transmitted diseases treatment guidelines, 2010". MMWR Recomm Rep. 59 (RR-12): 1–110. PMID 21160459.

Template:WH Template:WS